Deutsche Bank AG boosted its holdings in shares of CytRx Co. (NASDAQ:CYTR) by 1,076,287.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 86,111 shares of the biotechnology company’s stock after purchasing an additional 86,103 shares during the period. Deutsche Bank AG owned approximately 0.26% of CytRx worth $38,000 as of its most recent filing with the SEC.
CytRx stock traded down $0.00 during midday trading on Monday, hitting $0.34. 12,051 shares of the company’s stock were exchanged, compared to its average volume of 165,247. The stock has a market cap of $11.44 million, a PE ratio of -1.17 and a beta of 2.16. The business has a 50 day moving average price of $0.44. CytRx Co. has a 12-month low of $0.26 and a 12-month high of $1.29.
CytRx (NASDAQ:CYTR) last issued its earnings results on Wednesday, May 15th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. Equities analysts forecast that CytRx Co. will post -0.24 EPS for the current year.
CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The company is developing its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (linker activated drug release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of anti-cancer therapies.
Featured Article: What is a Market Correction?
Receive News & Ratings for CytRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx and related companies with MarketBeat.com's FREE daily email newsletter.